Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chru - Hôpital Du Haut Lévêque
Bordeaux, France
- Chru Dijon
Dijon, France
- Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, France
- Chru - Hôpital Claude Huriez
Lille, France
- Nantes University Hospital
Nantes, France
- Hôpital Saint-Antoine
Paris, France
- Centre Hospitalier Lyon Sud
Pierre-Bénite, France
- Pole Iuc Oncopole Chu
Toulouse, France
- Chru - Hôpital Bretonneau
Tours, France
- Chru - Hôpitaux de Brabois
Vandœuvre-lès-Nancy, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Nov 2014
- Primary completion
- 31 Mar 2019
- Completion
- 4 Jun 2020
- Last update posted
- 3 Aug 2023
- Registered enrollment
- 42
- Registry id
- NCT01936532
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.